← All trials
NCT02179294
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2014
- Primary completion
- Sep 1, 2016
- Completion date
- Sep 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 401
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of BirminghamLead sponsor
- Sheffield Hallam UniversityOverall official - principal investigator
- University of BirminghamSponsor investigator
- University of BirminghamCollaborator
- Stoke Mandeville HospitalCollaborator
- Warwick HospitalCollaborator
- University of WarwickCollaborator
- Frimley Park Hospital NHS TrustCollaborator
- Keele UniversityCollaborator
- University of East AngliaCollaborator
- York UniversityCollaborator
- University of LeedsCollaborator
- University of LondonCollaborator
- Medway NHS Foundation TrustCollaborator
- Barts & The London NHS TrustCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.